Navigation Links
Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma
Date:1/17/2008

Results underscore promise of radioimmunotherapy in ASCT and warrant

randomized trial

SEATTLE, Jan. 17 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced today that results of a phase II clinical study, published in the Journal of Clinical Oncology demonstrate that the addition of radioimmunotherapy (RIT) to high-dose chemotherapy (HDC) followed by autologous stem-cell transplantation (ASCT) produced a high rate (70 percent) of progression-free survival at two years without a significant increase in the toxicity of the HDC regimen underscoring the potential role for RIT in ASCT. Total-body irradiation (TBI) has previously been shown to significantly increase progression-free survival when added to HDC followed by ASCT as compared to HDC alone. However, TBI has long term complications and not all patients are eligible to receive TBI as part of their preparative regimen. Radioimmunotherapy with Zevalin(R) (Ibritumomab Tiuxetan), approved for follicular, low grade NHL which relapsed following 1st line rituximab based therapy, allows high doses of lymphoma-targeted radiation with lower doses to normal tissues.

The study, conducted at the City of Hope Comprehensive Cancer Center, used a single dose of Zevalin in patients undergoing ASCT following HDC with the BEAM regimen (carmustine, cytarabine, etoposide, and melphalan). Thirty-seven of the 41 patients had failed prior rituximab therapy. Seven of the ten patients transplanted in partial remission (70 percent) converted to complete remissions following the Zevalin-based regimen. The addition of Zevalin to the BEAM regimen did not appear to add to the toxicity of HDC; the day 100 mortality rate was zero (0) percent. Importantly the 2-year overall and progression-free survival estimates were approximately 89 percent and 70 percent, respectively.

"The promise of utilizing targeted radioimmunotherapy together with high-dose ch
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
2. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
3. Genasense(R) Can be Administered by Brief High-Dose IV Infusion
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
7. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the world,s ... dental, animal health and medical practitioners, announced today that the ... , September 4, 2014 – Baird 2014 Healthcare Conference ... ET , September 8, 2014 – Morgan ... , NY at 1:25 p.m. ET Henry Schein,s ...
(Date:8/21/2014)... PARK, N.J. , Aug. 21, 2014 /PRNewswire/ ... pharmacy group purchasing organization (GPO), is pleased to ... to collaborate on a host of innovative specialty ... help Aurora deliver enhanced therapy management services to ... Management (OTM) system. Aurora will use ...
(Date:8/21/2014)... WOONSOCKET, R.I. , Aug. 21, 2014 CVS ... early tender results, applicable Reference Yields and consideration payable in ... Offers") commenced on August 7, 2014 for (1) any and ... and All Notes") and (2) up to a maximum amount ... due 2041 and 5.750% Senior Notes due 2017 (collectively, the ...
Breaking Medicine Technology:Henry Schein To Present At Two Investor Conferences In September 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6
... Ill., Nov. 8, 2010 ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... 8, 2010 Reportlinker.com announces that a ... its catalogue: The Future ... leading companies, and opportunities for target expansion ... G-Protein-coupled receptors (GPCRs) constitute the largest ...
Cached Medicine Technology:Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 2Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 3Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 4Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 5Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 6Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 7Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 8The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 2The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 3The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 4The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 5
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... American Corporate Health, was recently recognized as ... professionals in the field of workers’ compensation. ... Workers’ Compensation and Occupational Medicine Conference was ... attorneys, physicians, nurses, case managers, disability specialists, ...
(Date:8/21/2014)... As part of a continuing mission to ... joined with the Alliance for Safe Online Pharmacies (ASOP) ... sale of medicines. , “Helping to ensure the quality, ... a core mission for USP and an important tool ... T. Piervincenzi, chief executive officer of USP. “The illegal ...
(Date:8/21/2014)... 21, 2014 According to a new ... Optics Market-Global Industry Analysis, Size, Share, Growth, Trends and ... market was valued at USD 863.1 million in 2013 ... 7.6% from 2013 to 2019, to reach an estimated ... medical fiber optics market is witnessing significant growth due ...
(Date:8/21/2014)... According to a new market report ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast, ... valued at USD 236.1 million in 2011 and is ... in 2018 at a CAGR of 6.3% from 2012 ... Report: http://www.transparencymarketresearch.com/fundus-cameras.html . , Fundus cameras market growth ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 The worlds ... offer customers an exciting chance to grab free products. ... all-natural deodorant from Tom's of Maine with all qualifying ... deodorant and our environmentally friendly yoga apparel is simply ... The joint promotion between the two brands is intended ...
Breaking Medicine News(10 mins):Health News:Dr. Vasili Gatsinaris Named One of the Top 50 Most Influential in Workers’ Compensation 2Health News:USP Joins Efforts to Halt Illegal Online Drug Sales 2Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 2Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 3Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 4Health News:Fundus Cameras Market: Product Type- Mydriatic, Non-Mydriatic, Hybrid and ROP Cameras; End Users- Hospitals, Ophthalmology Clinics and Ophthalmic & Optometrist Offices 2Health News:Tom's of Maine Partner up with BaliniSports Yoga Apparel 2
... and Company) (NYSE: BDX ), a global medical ... Bear Stearns 20th Annual,Healthcare Conference on Monday, September 10, ... of BD,s presentation can be accessed from the BD,corporate ... for replay,through Monday, September 17, 2007. BD, a ...
... Pa., Aug. 30 As part of his work,to ... health,insurance, Governor Edward G. Rendell today said 35,000 uninsured,individuals ... Insurance,Program will be given the opportunity to receive health ... insurance brings a sense of security and peace of ...
... pathway in the most common and aggressive type of ... to fuel tumor growth and help cancers evade drug ... In a series of laboratory and animal experiments, Johns ... with an experimental compound called cyclopamine to explore the ...
... reduce or prevent allergic reactions, group suggests , THURSDAY, ... people with seasonal allergies may suffer oral allergy syndrome ... pollen proteins from weeds, grass and trees and similar ... symptoms of OAS -- also known as pollen-food syndrome ...
... The sort of swelling that occurs when a joint ... the healing process, but when it comes to the knee, ... findings in experiments with pigs may lead to treatments for ... Medical Center orthopedic researchers. There are drugs that can block ...
... with the respiratory condition , , WEDNESDAY, Aug. 29 (HealthDay ... guidelines Wednesday that seek to make breathing easier and ... the lung disease. , "Asthma control is achievable for ... the National Heart, Lung, and Blood Institute, said during ...
Cached Medicine News:Health News:Governor Rendell Offers adultBasic Coverage to 35,000 Uninsured Pennsylvanians 2Health News:Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells 2Health News:Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells 3Health News:Pollen, Fruits, Veggies Help Trigger Oral Allergy Syndrome 2Health News:New insights into common knee injuries 2Health News:New Asthma Guidelines Stress Disease Control 2Health News:New Asthma Guidelines Stress Disease Control 3
For the quantitative determination of Glycohemoglobin in blood....
For the quantitative determination of Glycohemoglobin (HbA1) in blood by,cation exchange resin. The test is to be used to monitor long-term glucose,control in diabetes mellitus....
... storage protein for iron. The ferritin molecule ... of heavy and light subunits, which surrounds ... phosphate [1]. Ferritin is synthesized in the ... with major concentrations found in the liver, ...
Rapid turn-around time, results in less than 4 hours...
Medicine Products: